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Tuberculosis (TB) has afflicted mankind for millennia and continues 
to be a major public health burden. In 2015, an estimated 10.4 million 
people contracted TB and up 1.8 million people succumbed to the 
disease.[1] The vast majority of TB cases occur in low- and middle-
income countries, particularly those where there is an intersection 
of the TB epidemic and the HIV epidemic.[2] There have recently 
been major advances in the diagnostics and treatment of TB.[3,4] 
Consequently, the mortality associated with TB dropped by at least 
47% from 1990 to 2015.[1]
The lungs are the most common site of TB infection, and up to 81% 
of reported TB cases are pulmonary TB (PTB).[5] TB cure is defined 
as the sterility of body sites or specimens previously infected by 
Mycobacterium tuberculosis or completion of a predetermined dose 
and duration of TB therapy.[6,7] However, a substantial proportion of 
patients (40 - 97%[8-13]) continue to experience respiratory symptoms 
long after completion of therapy. In addition, 40 - 100% of patients 
with previous PTB are reported to have persistent chest radiographic 
abnormalities.[8,13,14] Older age, female sex, longer duration of 
symptoms prior to the commencement of therapy, poor compliance 
with therapy and a history of previous PTB are factors associated with 
poor radiographic resolution after completion of therapy.[15]
Objectives
The clinical implications of residual respiratory symptoms in post-TB 
patients in resource-constrained settings are unknown. Moreover, 
there are no guideline recommendations on the management of 
post-TB lung disease. The objective of this study was to describe the 
clinical profile and in-hospital outcomes of patients with chronic lung 
disease (CLD) and a documented history of previous PTB (CLD-
TB) compared with patients with CLD and no history of PTB, in a 
resource-constrained setting.
Methods
Study design
This study was a retrospective review of patients admitted to the 
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Background. Many patients with previous pulmonary tuberculosis (PTB) continue to experience respiratory symptoms long after completion 
of tuberculosis (TB) therapy, often resulting in numerous hospital visits and admissions.
Objectives. To describe the profile of patients with chronic lung disease (CLD) with or without a history of PTB, and their in-hospital outcomes.
Methods. We conducted a retrospective review of patients with CLD admitted with respiratory symptoms to Dora Nginza Hospital, Port 
Elizabeth, South Africa, from 1 April 2016 to 31 October 2016. These patients were divided into two groups: CLD with a history of PTB 
(CLD-TB) and CLD without a history of PTB. Patients with current culture-positive TB were excluded. Baseline characteristics and clinical 
outcomes (duration of hospitalisation and in-hospital mortality) were compared between the two groups.
Results. During the study period, a total of 4 884 patients were admitted and 242 patients received a diagnosis of CLD. In the CLD patient 
group, 173 had CLD-TB and 69 had no history of PTB. Patients with CLD-TB presented with respiratory symptoms a median of 41 months 
(interquartile range (IQR) 101) after completion of TB therapy. CLD-TB patients were predominantly male (59.5%), and compared with 
patients with no history of PTB were more likely to be HIV-positive (49.7% v. 8.7%; p=0.001) and had had more frequent hospital admissions 
before the current admission (median 2.0 (IQR 2.0) v. 0; p=0.001) and longer hospital stays (median 5 days (IQR 7) v. 2 (4); p=0.002). 
However, there was no statistically significant difference in in-hospital mortality between the two groups (17.3% v. 10.1%; p=0.165).
Conclusions. In patients with CLD, a history of PTB is associated with numerous hospital admissions and longer hospital stays but not with 
increased in-hospital mortality. TB therefore continues to be a public health burden long after cure of active disease.
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to 31 October 2016. Dora Nginza Hospital 
is a district hospital in Zwide township in 
the Nelson Mandela Bay Municipality (Port 
Eliza beth), South Africa. In 2011 Nelson 
Mandela Bay had a population of 1 152 115 
and an up to 36.6% unemployment rate. [16] 
The Department of Medicine at the hospital 
is a 120-bed unit with no intensive care 
or high-care unit and limited access to 
radiological imaging other than plain chest 
radiography.
Study population
Clinical notes, discharge summaries and the 
death notification registry were reviewed to 
identify patients who received a primary or 
secondary diagnosis of CLD. The patients 
identified were then divided into two 
groups: (i) CLD-TB; and (ii) CLD with no 
documented history of previous PTB. All 
patients with a current diagnosis of culture-
positive TB were excluded (n=905). The 
study was approved by the Walter Sisulu 
University Human Research Committee (ref. 
no. 005/2017). Informed consent was waived 
because this was a retrospective study.
Data collection
A standardised data collection form that 
included patient demographic details, 
comorbidities, history of previous PTB, 
time in months since completion of anti-
TB therapy for the last episode of PTB, and 
details of the index admission was used. 
Blood results and sputum microbiology 
results were retrieved from the National 
Health Laboratory Service database. 
Sputum culture micro-organisms are only 
reported for specimens with >25 neutro-
phils and ≤10 epithelial cells per 100 × 
magnification on Gram stain microscopy. [17] 
Admission chest radiographs from the 
Dora Nginza Hospital Picture Archiving 
and Communications System were reviewed 
and graded for the extent of radiographic 
abnormalities as described by Willcox and 
Ferguson.[18] Briefly, each lung was divided 
into three zones, upper, middle and lower, 
by horizontal lines dividing the vertical 
distance from the pulmonary apex to the 
hemidiaphragm into three equal parts. 
Grade l disease was minimal involvement 
with one zone involved without cavitation, 
grade 2 disease was involvement of two or 
three zones or one zone with cavitation, 
and grade 3 disease was severe involvement 
with more than three zones involved with or 
without cavitation.[18] The chest radiographs 
and electrocardiograms (ECGs) (when 
the latter were available) were assessed by 
two doctors and disputes were settled by a 
third doctor. ECGs were assessed for heart 
rhythm, evidence of right atrial abnormality 
and ventricular hypertrophy. Right atrial 
abnormality was defined as a P-wave 
height ≥0.25 mV[19] and right ventricular 
enlargement as an R wave in V1 ≥0.7 mV 
and an R/S ratio ≥1 in V1 with an R wave 
≥0.5 mV (dominant R wave in V1).[19]
Statistical analysis
Normally distributed continuous variables 
are reported as means (standard deviations 
(SDs)) and as medians (interquartile ranges 
(IQRs)) when skewed. Discrete data are 
presented as numbers and percentages. 
Student’s t-test, the Mann-Whitney U-test 
and the corresponding 95% confidence 
intervals were used to calculate the difference 
between the two groups, a p-value <0.05 
was set as significant, and Pearson’s χ2 test 
was used to compare categorical variables 
between the two groups. Statistical analyses 
were performed using SPSS Statistics for 
Macintosh version 24.0 (IBM, USA).
Results
During the study period, 4 884 patients were 
admitted by the Department of Medicine at 
Dora Nginza Hospital. A total of 745  patients 
died in hospital, and 905 patients with culture-
positive TB were excluded from the study. 
Among the remaining patients, 242 patients 
with CLD were identified, of whom 173 
(71.5%) had CLD-TB and 69 (28.5%) had 
no history of PTB (Fig. 1). The patients with 
CLD-TB had a mean (SD) age of 50.8 (15.1) 
years, and 59.5% were male; compared with 
patients with CLD and no history of PTB, 
they were more likely to be HIV-positive 
(49.7% v. 8.7%; p<0.001) (Table  1), had more 
frequent hospital admissions during the 
12 months preceding the current admission, 
and had longer hospital stays during the 
index hospitalisation (Table 1).
Fig. 2 shows the frequency of documented 
symptoms and signs in the 173 patients 
with CLD-TB. Dyspnoea was the most 
common presenting symptom, reported 
in 81.5%, followed by a cough productive 
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Fig. 1. Study flow chart. (TB = tuberculosis; CLD = chronic lung disease; PTB = pulmonary tuberculosis.)
Table 1. Demographic characteristics of patients with chronic lung disease
History of TB 
(N=173)
No history of TB
(N=69) p-value 
Age (years), mean (SD) 50.8 (15.1) 54.0 (18.2) 0.067
Female, n (%) 70 (40.5) 37 (53.6) 0.063
HIV-positive, n (%) 86 (49.7) 6 (8.7) 0.001
Hypertension, n (%) 49 (28.3) 26 (37.7) 0.157
Diabetes mellitus, n (%) 10 (5.8) 6 (8.7) 0.413
Previous admissions (n), median (IQR) 2.0 (2.0) 0 0.001
Duration of current hospitalisation (days), median (IQR) 5 (7) 2 (4) 0.002
In-hospital mortality, n (%) 30 (17.3) 7 (10.1) 0.165
Time since completion of TB therapy (months), median (IQR) 41 (101) - - 
TB = tuberculosis; SD = standard deviation; IQR = interquartile range.
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of purulent sputum, reported in 51.4%; 
haemoptysis was only reported in 18.5%. All 
173 CLD-TB patients had chest radiographs 
available. Fibrosis was present in 48.0%, 
hyperinflation in 53.2%, pleural reactions 
in 72.8%, bronchiec tasis changes in 83.3%, 
and a cardio thoracic ratio >50% in 33.5% 
(Table 2). Only 4.0% of CLD-TB patients had 
normal chest radiographs, and 69.9% had 
grade 3 disease according to the classification 
of Willcox and Ferguson[18] (Fig. 3). All 
patients had a sputum GeneXpert test, a 
smear for acid-fast bacilli and tuberculosis 
culture. Sputum culture for M. tuberculosis 
was negative in all cases. However, the 
sputum GeneXpert test and the smear for 
acid-fast bacilli were positive in 9.0% and 
4.0% of the CLD-TB cohort, respectively. 
Haemophilus influenzae was cultured in 
29.1% of the 117 patients whose sputum had 
≥25 neutrophils and ≤10 epithelial cells per 
low-power field on Gram stain and was sent 
for routine microscopy and culture (Fig. 4).
Twelve-lead ECGs were available for 73 
patients with CLD-TB. Multifocal atrial 
tachycardia was the most prevalent rhythm 
(78.1%), followed by sinus rhythm in only 
13.7%. Atrial fibrillation and atrial flutter 
were present in 6.8% and 1.4%, respectively. 
Right atrial abnormality, defined above,[19] 
was present in 49.7%, and P-wave right axis 
deviation was present in 74.0%. Additionally, 
right ventricular enlargement, defined as an 
R wave in V1 >0.7 mV and an R/S ratio >1 
with R >0.5 mV,[19] was present in 21.9% and 
24.7%, respectively. We could not identify 
predictors of in-hospital mortality in our 
study (Fig. 5).
Discussion
The key findings of our study were as follows: 
(i) a large proportion of patients with CLD 
in our cohort had had previous PTB; 
(ii)  CLD-TB patients were predominantly 
male; (iii) CLD-TB patients were more likely 
than CLD patients without a history of PTB 
to be HIV-positive; (iv) CLD-TB patients 
had longer hospital stays than CLD patients 
without a history of PTB; (v) in CLD-TB 
patients in whom routine sputum microscopy 
and culture was done, H.  influenzae was the 
most frequently cultured micro-organism; 
and (vi) multifocal atrial tachycardia was 
the predominant rhythm in CLD-TB 
patients who had an ECG, and a substantial 
proportion of patients had ECG evidence of 
right atrial hypertrophy and right ventricular 
hypertrophy.
This article is the first to report sputum 
micro-organisms in a patient population with 
CLD-TB. The patients had numerous sputum 
micro-organisms cultured. H. influenzae was 
the most frequently isolated sputum micro-
organism (29.1%), followed by Pseudomonas 
aeruginosa and Klebsiella pnuemoniae (9.4% 
and 7.7%, respectively). Only 13.7% of the 
patients with CLD-TB who had routine 
sputum culture had culture-negative sputum. 
The presence of sputum micro-organisms, 
particularly P. aeruginosa, in patients with 
non-cystic fibrosis bronchiectasis predicts 
a poor clinical outcome characterised by 
a progressive decline in lung function and 
recurrent severe exacerbations of respiratory 
symptoms.[20] In addition, there is evidence 
 
 
 
 
Digital clubbing
Pitting pedal oedema
Chest pain
Dyspnoea
Dry cough
Purulent sputum
Haemoptysis
                                                        46.2
           30.1
    20.8
                                         81.5
  19.7
                                                                   51.4
19.5
0                 10                 20              30              40              50              60              70              80              90
Frequency, %
Grade 3
Grade 2
Grade 1
Normal chest
radiograph
              69.9
    16.8
        9.2
4.0
0            10           20            30            40            50            60           70           80
Ra
di
og
ra
ph
ic
 g
ra
de
Frequency, %
Patients admitted 1 April 2016 - 31 October 2016
N=4 884
Patients with a diagnosis of CLD
n=242
Patients with a history of PTB
n=173
Patients without a history of PTB
n=69
Patients with culture-positive TB, excluded
n=905
Cl
in
ic
al
 s
ym
pt
om
s 
an
d 
si
gn
s
Fig. 2. Documented clinical symptoms and signs at presentation in patients with chronic lung disease 
and a history of pulmonary tuberculosis (N=173).
Table 2. Chest radiographic findings in patients with chronic lung disease and a 
history of pulmonary tuberculosis (N=173)
Variable n (%)
Fibrosis and traction 83 (48.0)
Pneumothorax 7 (4.0)
Bronchiectasis changes 145 (83.8)
Cavities
Single 28 (16.2)
Multiple 31 (17.9)
Destroyed lung 15 (8.7)
Hyperinflation 92 (53.2)
Cardiothoracic ratio >50% 58 (33.5)
Pleural reaction 126 (72.8)
Radiographic grade[18]
Normal chest radiograph 7 (4.0)
Grade 1 16 (9.2)
Grade 2 29 (16.8)
Grade 3 121 (69.9)
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Fig. 3. Chest radiographic grade[18] of patients with chronic lung disease and a history of pulmonary 
tuberculosis (N=173).
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that eradication of such micro-organisms 
leads to fewer exacerbations and therefore 
fewer hospitalisations.[21,22] Such treatment 
presents a viable management strategy 
for patients with CLD-TB in resource-
constrained settings to curb the costs of 
recurrent admissions and long hospital stays.
Historically, ECG changes have been 
reported in the setting of chronic obstruc-
tive pulmonary disease (COPD). To our 
knowledge, this is the first study to report 
ECG changes in patients with CLD-
TB. A P wave ≥0.25 mV in leads I, II 
and AVF, a P-wave axis ≥80o and a QRS 
axis  ≥90o have traditionally been regarded 
as ECG manifestations associated with 
COPD. [23] Furthermore, the presence of 
P  waves ≥0.25  mV in the inferior leads 
has been found to correlate with moderate 
to severe lung disease[24] and a P-wave 
axis  ≥70o has been associated with severe 
lung disease. [25,26] In the present study, we 
found a P wave ≥0.25 mV to be present in 
49.7% of patients with CLD-TB and P-wave 
right axis deviation to be present in 74.0%. 
Additionally, right ventricular enlargement 
was present in 21.9  - 24.7% of the patients 
with available ECGs, depending on the 
criteria used. However, EGC changes did 
not predict in-hospital outcome or severity 
of lung disease as defined by the Willcox and 
Ferguson[18] grading system.
Disability and ill health from tuberculosis 
persist beyond the period of active disease. 
In a population of 3 993 patients with fully 
treated TB, Hoger et al.[27] reported an average 
of 3.6 more years of potential life lost than in 
a similar population without a history of 
TB. Furthermore, Miller et al.[28] estimated 
that chronic morbidity accounted for 78% 
of quality-adjusted life-years (QALYs) lost 
in patients with cured TB; acute illness and 
mortality were responsible for only 4% and 
18% of QALYs lost, respectively. Although 
we found no statistically significant 
difference in hospital mortality in patients 
with CLT-TB compared with those with 
CLD and no previous PTB (17.3% v. 10.1%; 
p=0.165), patients with CLD-TB had more 
frequent and longer hospital admissions, 
highlighting the impact of previous TB on 
quality of life and on public health. The 
presence of residual respiratory symptoms 
after completion of PTB therapy has been 
widely reported, with a prevalence of up to 
97%.[8,11-13] Musafiri et al.[13] reported that 
these symptoms can persist up to a year after 
the completion of TB therapy, Our patients 
were admitted with respiratory symptoms 
after a median of 41 months (IQR 101) after 
completion of TB therapy.
Complete resolution of chest radiographic 
abnormalities after completion of PTB 
therapy is reported in only 59.6% of fully 
treated patients.[14] Residual parenchymal 
changes account for the majority of residual 
chest radiographic abnormalities after 
completion of PTB therapy, while pleural and 
mediastinal abnormalities account for 23.6% 
and 9.0%, respectively.[14] Cardiotopographic 
imaging identifies 5% more residual 
pleural abnormalities than plain chest 
radiography. [29] Of our patient cohort, 96.0% 
had abnormal chest radiographs.
The respiratory physiological manifes-
tations of post-TB lung disease are 
varied. [18,30] In a cross-sectional study by 
Mbatchou Ngahane et al.[30] of 269 patients 
successfully treated for PTB, only 54.6% of 
the cohort had normal lung function tests. 
The remainder of the patients had restrictive 
(31.6%) or obstructive changes (4.1%) 
or a mixed pattern (5.2%). Willcox and 
Ferguson[18] reported obstructive changes in 
68% of their patients and restrictive changes 
in 17%, while 15% had normal lung function 
tests. Lung function testing revealing 
obstructive changes and bronchodilator 
response therefore offers a viable therapeutic 
strategy that needs to be studied further in 
this patient population. We do not have lung 
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Fig. 4. Micro-organisms cultured on routine microscopy and culture in patients with chronic lung 
disease with a history of pulmonary tuberculosis whose sputum had ≥25 neutrophils and ≤10 epithelial 
cells per low-power field on Gram stain (N=117).
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Fig. 5. Relative risk (confidence intervals) of in-hospital death in patients with chronic lung disease with 
a history of pulmonary tuberculosis.
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function results for our cohort, partly owing to unavailability of this 
form of testing in our hospital. Finally, long-term oxygen therapy 
has been shown to improve survival, reduce hospital readmission 
rates and improve quality of life in hypoxic stable chronic obstructive 
airway disease (COAD)[31,32] and is recommended in our local 
guidelines for the management of hypoxic COAD.[33] However, it is 
still to be investigated in post-TB lung disease with hypoxia.
Study limitations
The limitations of this study are its retrospective and single-centre 
nature, the lack of long-term follow-up and lack of lung function 
testing, absence of data on hospital visits outside our unit, and 
the facts that few patients had ECGs and we did not report on 
the prevalence of hypoxia as measured by arterial blood gases. 
Additionally, we do not have information on patients who may have 
been treated empirically for TB on the basis of their abnormal chest 
radiographs while awaiting sputum results.
Conclusions
The objective of this study was to describe the clinical profile and 
in-hospital outcomes of patients with CLD-TB compared with 
patients with CLD and no history of PTB in a resource-constrained 
setting. We found that patients with CLD-TB had persistent respiratory 
symptoms, residual abnormal findings on chest radiographs, and 
ECG evidence of right atrial and right ventricular enlargement. In 
addition, they were more likely to have recurrent hospital admissions 
than patients with CLD without previous pulmonary TB. Although 
there was a trend towards increased in-hospital mortality, this was 
not statistically significant.
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